EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Platform · Demonstration 4 · One program, every stage

One curcumin program, eight connected decisions

Three demonstrations examine single stages (extraction, consistency and solubility), and a decision tree covers the intake screen. This one follows a single hypothetical program, a turmeric extract for a U.S. dietary supplement, from the intake screen through all eight stages of the Ingredient Engine. Each decision rests on published data, and each one narrows or reopens a later stage.

Hypothetical exampleEUTECNIQ is in formation and has run no program. The client, the decisions and the serving are hypothetical; every measurement is from a cited study, and every rule from a cited regulation or specification.

The same turmeric, four solvents: how much oleoresin, and how rich in curcuminoids

One laboratory, one milled Peruvian rhizome, mean ± SD of three extractions. Dashed curves join equal recovery of curcuminoids from the rhizome.

Scatter of four extraction solvents on the same milled turmeric (Barriga-Sánchez et al. 2024): oleoresin yield against total curcuminoids in the oleoresin, mean ± SD, n = 3. Acetone 21.44% yield, 35.85% curcuminoids; supercritical CO₂ with 30% ethanol 21.21%, 33.43%; methanol 26.49%, 29.31%; ethanol 25.43%, 25.81%. Dashed curves join equal recovery, yield times content: 6.5, 7.0, 7.5 and 8.0 g curcuminoids per 100 g rhizome.2426283032343638Total curcuminoids in the oleoresin, g per 100 g2022242628Oleoresin yield, % of milled rhizome6.57.07.58.0Acetone: yield 21.44%, curcuminoids 35.85 g/100 g, recovery 7.69 ± 0.46 g per 100 g rhizomeSupercritical CO₂, 30% ethanol: yield 21.21%, curcuminoids 33.43 g/100 g, recovery 7.09 ± 0.54 g per 100 g rhizomeMethanol: yield 26.49%, curcuminoids 29.31 g/100 g, recovery 7.76 ± 0.35 g per 100 g rhizomeEthanol: yield 25.43%, curcuminoids 25.81 g/100 g, recovery 6.56 ± 0.27 g per 100 g rhizomeAcetone: 7.69 gSupercritical CO₂, 30% ethanol: 7.09 gMethanol: 7.76 gEthanol: 6.56 gRecovery, g per 100 g rhizome (dashed)Scatter of four extraction solvents on the same milled turmeric (Barriga-Sánchez et al. 2024): oleoresin yield against total curcuminoids in the oleoresin, mean ± SD, n = 3. Acetone 21.44% yield, 35.85% curcuminoids; supercritical CO₂ with 30% ethanol 21.21%, 33.43%; methanol 26.49%, 29.31%; ethanol 25.43%, 25.81%. Dashed curves join equal recovery, yield times content: 6.5, 7.0, 7.5 and 8.0 g curcuminoids per 100 g rhizome.2426283032343638Total curcuminoids in the oleoresin, g per 100 g2022242628Oleoresin yield, % of milled rhizome6.57.07.58.0Acetone: yield 21.44%, curcuminoids 35.85 g/100 g, recovery 7.69 ± 0.46 g per 100 g rhizomeSupercritical CO₂, 30% ethanol: yield 21.21%, curcuminoids 33.43 g/100 g, recovery 7.09 ± 0.54 g per 100 g rhizomeMethanol: yield 26.49%, curcuminoids 29.31 g/100 g, recovery 7.76 ± 0.35 g per 100 g rhizomeEthanol: yield 25.43%, curcuminoids 25.81 g/100 g, recovery 6.56 ± 0.27 g per 100 g rhizomeAcetone: 7.69 g per 100 gSupercritical CO₂, 30% ethanol: 7.09 g per 100 gMethanol: 7.76 g per 100 gEthanol: 6.56 g per 100 gDashed: equal recovery, g per 100 g rhizome
Measured data Barriga-Sánchez et al., Food Sci Technol (Campinas) 2024, Tables 3 and 4. Recovery (yield × content) is arithmetic done for this page, not a value the paper reports. Stage 3.

Run the program

Change any of five decisions and watch the program proceed, reopen stages or stop

Each control is one decision in the program. The stage bar and the verdict update at once; the evidence behind every rule is set out in the sections below.

Stage 2 · Identity method
Stage 3 · Solvent
Stage 5 · Formulation
Stage 6 · Serving
Stage 7 · Drying temperature
  1. 0Intake
  2. 1Discover
  3. 2Source
  4. 3Extract
  5. 4Specify
  6. 5Deliver
  7. 6Safety
  8. 7Scale
  9. 8Market

SettledReopenedRejected

Hypothetical example Values are from the studies and rules cited in sections 02 to 07; the reopen and reject rules are the decisions argued on this page, not regulatory requirements. Run the same program on the eight-stage workspace, where each stage shows its record.

01 · The program

A brand wants a turmeric extract it can document, and every stage constrains the next

The hypothetical client is a U.S. supplement brand that wants a turmeric extract capsule whose identity, curcuminoid content and absorption it can document. It enters as a development program (see Ways into the Engine). The chain below shows the decision taken at each stage and five constraints that one stage hands to a later one.

Decision chain of the hypothetical curcumin program across the intake screen and eight Engine stages, with the decision at each stage and five numbered constraints that one stage passes to a later one: 1, Stage 5 to Stage 6: A higher-exposure formulation reopens the safety case; 2, Stage 3 to Stage 4: The solvent sets the residue test; 3, Stage 2 to Stage 4: Lead and synthetic-curcumin tests enter the specification; 4, Stage 3 to Stage 7: Heat degrades curcumin; keep evaporation well below 80 °C until degradation is measured; 5, Stage 0 to Stage 8: The route chosen at intake is confirmed before any claim is made.0IntakeSupplementroute; nodiseaseclaims1DiscoverKnownbotanical;threecurcuminoids2SourceIsotope testfor synthetic;lead per lot3ExtractAcetone, notmethanol4SpecifyHPLC assay;residualacetone; leadlimit5DeliverTwocandidates;piperinerejected6SafetyExposure-based casefor thechosen form7ScaleEvaporatewell below 80°C; recoveracetone8MarketSpec exhibit;processknow-how123451Stage 5 → Stage 6: A higher-exposure formulation reopens the safetycase2Stage 3 → Stage 4: The solvent sets the residue test3Stage 2 → Stage 4: Lead and synthetic-curcumin tests enter thespecification4Stage 3 → Stage 7: Heat degrades curcumin; keep evaporation wellbelow 80 °C until degradation is measured5Stage 0 → Stage 8: The route chosen at intake is confirmed before anyclaim is madeThe hypothetical curcumin program as a list: the decision at each Engine stage and the constraints it passes forward0Intake: Supplement route; no disease claims→ Stage 8: The route chosen at intake is confirmedbefore any claim is made1Discover: Known botanical; three curcuminoids2Source: Isotope test for synthetic; lead per lot→ Stage 4: Lead and synthetic-curcumin tests enterthe specification3Extract: Acetone, not methanol→ Stage 4: The solvent sets the residue test→ Stage 7: Heat degrades curcumin; keepevaporation well below 80 °C until degradation ismeasured4Specify: HPLC assay; residual acetone; lead limit5Deliver: Two candidates; piperine rejected→ Stage 6: A higher-exposure formulation reopensthe safety case6Safety: Exposure-based case for the chosen form7Scale: Evaporate well below 80 °C; recoveracetone8Market: Spec exhibit; process know-how
Educational schematic Decisions are those argued on this page for a hypothetical program; the constraints are drawn from the sources cited in each section.

0 Intake and feasibility screen

What the screen asks

  • Intended use: a dietary supplement. A product intended to treat or prevent disease is a drug (21 U.S.C. 321(g)(1)), so the label may carry structure/function statements with FDA’s disclaimer (21 CFR 101.93) and no disease claim.
  • Whether this extract is a new dietary ingredient, which needs a notification at least 75 days before marketing unless the food-supply exception applies (21 CFR 190.6). The answer depends on the extract’s history and manufacture, so the screen records it as a question for the client’s counsel.
  • A reference intake. JECFA set an acceptable daily intake (ADI) of 0–3 mg/kg body weight for curcumin as a food color in 2003, from a no-effect level of 250–320 mg/kg per day in a multigeneration rat study with a safety factor of 100 (WHO JECFA); EFSA reached 3 mg/kg per day in 2010 (EFSA). For a 70 kg adult, 3 mg/kg is 210 mg a day.

Decision

Proceed on the supplement route, with the serving to be set at Stage 6 against the exposure of the formulation actually chosen. The route is confirmed again before any label claim is made (Stage 8).

Passes forward: no disease claims; a reference intake that applies to conventional curcumin.

Published evidence The 70 kg body weight is an illustrative assumption. The ADI is for curcumin used as a food color; it is a reference point here, not a supplement dose limit set by any regulator.

02 · Stages 1 and 2 · Discover; authenticate the source

The chemistry is known; the risk is what the supply chain adds

Turmeric is not a discovery program. Its coloring principles are three curcuminoids: curcumin, demethoxycurcumin and bisdemethoxycurcumin. Reported content varies with origin: 2–9% curcuminoids (Priyadarsini 2014), 0.6–5% curcumin in the dry rhizome (EMA 2018) and 3–5% coloring principles (JECFA 2004). Stage 1 therefore ends quickly, with a candidate dossier and a target product profile.

Stage 2 carries the weight. Three published findings set the identity work:

  • Of 2,235 commercial turmeric samples in 48 published surveys (2000–2025), 20.0% were adulterated with dyes, undeclared diluents or synthetic curcumin. The surveys are pooled; this is not a market-wide rate (Gafner et al. 2026).
  • In Bangladesh, lead chromate pigment was added to turmeric in 7 of 9 major producing districts; turmeric powder reached 690 µg/g lead in those districts and 1,152 µg/g in Dhaka and Munshiganj (Forsyth et al. 2019).
  • In one set of 27 samples, HPLC content could not tell 6 synthetic curcuminoid samples from 21 natural ones; the hydrogen isotope ratio separated all of them (Perini et al. 2023).

Decision

Identity on each lot by HPTLC and microscopy for the rhizome, plus an isotope-ratio or carbon-14 test for synthetic curcuminoids on the extract; lead by ICP-MS on every lot. A supplier’s certificate is relied on only after its results are confirmed, and the confirmation is repeated periodically (21 CFR 111.75(a)(2)).

Rejected: accepting curcuminoid content by HPLC as proof of natural origin. In the Perini set it could not separate synthetic from natural material.

Passes forward to Stage 4: a lead limit and a synthetic-origin test in the specification.

03 · Stage 3 · Extract, separate and optimize

The solvent with the highest recovery is rejected, because the gain is within error and its residue benchmarks are stricter

One study extracted the same milled rhizome with four solvents. Methanol gave the most oleoresin, acetone and supercritical CO₂ the richest. Multiplying the two gives the curcuminoids recovered per 100 g of rhizome, and the differences between the top three fall within their uncertainty.

Four solvents on the same milled turmeric: published yield and content, recovery computed here, and the residue benchmarks each would bring
SolventOleoresin yield, %Curcuminoids in oleoresin, g/100 gRecovered, g per 100 g rhizomeResidue benchmarks (none is a supplement rule)
Acetone21.44 ± 0.5135.85 ± 1.977.69 ± 0.46≤ 30 ppm tolerance for spice oleoresins (21 CFR 173.210); ≤ 30 mg/kg in the JECFA specification for curcumin as a food color; ICH Q3C class 3
Supercritical CO₂ with 30% ethanol modifier21.21 ± 1.2033.43 ± 1.707.09 ± 0.54No CO₂ residue, but the 30% ethanol modifier must be recovered and its residue tested (JECFA groups ethanol at ≤ 50 mg/kg); 350 bar in the study
Methanol26.49 ± 0.5229.31 ± 1.207.76 ± 0.35≤ 50 ppm tolerance for spice oleoresins (21 CFR 173.250); ≤ 50 mg/kg (JECFA); ICH Q3C class 2, “solvents to be limited”
Ethanol25.43 ± 0.6525.81 ± 0.856.56 ± 0.27Grouped at ≤ 50 mg/kg by JECFA; ICH Q3C class 3

Measured data Yield and content: Barriga-Sánchez et al. 2024, Tables 3 and 4 (mean ± SD, n = 3; conventional solvents by repeated ultrasonic extraction at 1:5 w/v; CO₂ at 350 bar, 65 °C, 150 min). Recovery and its ± are computed here (product of the means; first-order propagation assuming independent errors). Benchmarks: 21 CFR 173.210, 173.250; JECFA specification (2003); ICH Q3C(R9).

Which of these limits apply to a supplement? None was written for one. 21 CFR 173.210 and 173.250 are food additive tolerances for spice oleoresins. The JECFA specification covers curcumin used as a food color, and ICH Q3C is guidance for medicines. For a dietary supplement, the manufacturer must itself set “limits on those types of contamination that may adulterate or may lead to adulteration” of the finished batch (21 CFR 111.70(b)(3)). The values in this table are benchmarks a manufacturer could adopt as its own specification, and the residue limits used below are proposals on that basis. Whether any of these rules reaches a particular product is a question for the client’s counsel.

What else this stage passes on

Curcumin degrades with heat. In a microwave-extraction study, curcumin concentration fell when the temperature passed 80 °C, which the authors attributed to stepwise degradation (Bener et al. 2016). The extraction study above evaporated its solvents at 40 °C. That study measured microwave extraction in aqueous methanol, not evaporation or drying, so 80 °C is a warning for those later steps, not a validated limit.

The richest oleoresin here holds about 36% curcuminoids. JECFA’s grade for curcumin as a color is at least 90% total coloring matters, reached by further washing of the oleoresin (JECFA 2004). The higher the starting content, the less has to be removed.

Decision

Acetone extraction at laboratory scale. Supercritical CO₂ stays as the alternative for a client that wants to avoid acetone and accepts high-pressure equipment. It is not solvent-free as tested: the run above used 30% ethanol as a modifier, which must be recovered and its residue controlled, and CO₂ without a modifier was not tested in this study.

Rejected: methanol. Its recovery, 7.76 ± 0.35 g, is within error of acetone’s 7.69 ± 0.46 g; its oleoresin is poorer (29% against 36%), and it is a class 2 solvent.

Deferred: ethanol. It has the simplest residue profile but the poorest oleoresin (26%) and the lowest recovery.

Passes forward: a residual-acetone test against a proposed internal limit of 30 mg/kg to Stage 4; an evaporation-temperature limit and solvent recovery to Stage 7.

04 · Stage 4 · Characterize and standardize

The specification collects the constraints of Stages 2 and 3

Each line of the draft specification below exists because an earlier stage put it there. No U.S. rule fixes these limits for a supplement: the manufacturer sets them (21 CFR 111.70(b)). The values below are proposals adopted from food and food-color specifications, to be agreed with the client in the statement of work.

Draft specification for the hypothetical extract, with the stage that requires each line and its basis
TestMethodLimitRequired byBasis and status
Curcumin, demethoxycurcumin, bisdemethoxycurcuminHPLC, single-laboratory validated (AOAC First Action 2016.16)Client target, reported as each and as the totalStage 4Mudge and Brown 2018
Natural originHydrogen isotope ratio or carbon-14Within the natural reference rangeStage 2Perini et al. 2023
LeadICP-MS≤ 2 mg/kg, proposedStage 2Adopted from JECFA 2003 (food color); the EU E 100 limit is 10 mg/kg (Reg. (EU) 231/2012)
Residual acetoneGas chromatography≤ 30 mg/kg, proposedStage 3Adopted from the spice-oleoresin tolerance (21 CFR 173.210) and JECFA 2003; set under 21 CFR 111.70(b)(3)

JECFA assays curcumin as total coloring matters by absorbance at 425 nm (JECFA 2003). That returns one number for everything that absorbs there, so it cannot report the three curcuminoids separately, and like HPLC it cannot tell synthetic from natural curcumin.

Decision

Specify the three curcuminoids by validated HPLC, natural origin by isotope ratio, proposed limits of 2 mg/kg lead and 30 mg/kg residual acetone.

Rejected as the only assay: absorbance at 425 nm. It is kept, if at all, as a quick in-process check.

Identity gate: passed only when these methods work on real lots and the content holds within the agreed range lot to lot.

05 · Stage 5 · Engineer delivery

Curcumin barely dissolves in water, and the formulations that fix this change the safety question

PubChem lists curcumin as insoluble in water (PubChem). Formulations raise plasma exposure, but published comparisons differ in dose, analyte and design. The study below compared several formulations against the same reference extract.

Relative exposure to total curcuminoids, one study in 12 adults

Horizontal bars: relative exposure to total curcuminoids (AUC 0–12 h, after deconjugation, dose-normalized) in one study of 12 adults, Purpura et al. 2018: standard extract 1.0, turmeric oil formulation 1.1, phytosome 8.5, γ-cyclodextrin complex 39.1. Funded by a cyclodextrin supplier.Standard extract (reference)Standard extract (reference): 1.0×1×Turmeric oil formulationTurmeric oil formulation: 1.1×1.1×PhytosomePhytosome: 8.5×8.5×γ-Cyclodextrin complexγ-Cyclodextrin complex: 39.1×39.1×Times the standard extract's exposure; plasma levels, not effectsHorizontal bars: relative exposure to total curcuminoids (AUC 0–12 h, after deconjugation, dose-normalized) in one study of 12 adults, Purpura et al. 2018: standard extract 1.0, turmeric oil formulation 1.1, phytosome 8.5, γ-cyclodextrin complex 39.1. Funded by a cyclodextrin supplier.Standard extract (reference)Standard extract (reference): 1.0×1×Turmeric oil formulationTurmeric oil formulation: 1.1×1.1×PhytosomePhytosome: 8.5×8.5×γ-Cyclodextrin complexγ-Cyclodextrin complex: 39.1×39.1×Times the standard extract's exposure; plasma levels,not effects
Published evidence Purpura et al. 2018: AUC 0–12 h of total curcuminoids after deconjugation, dose-normalized against a standard extract given at about five times the dose; funded by Wacker Chemie AG. Plasma exposure is not a health effect.

Why piperine is rejected here

  • The widely cited 2,000% increase with 20 mg piperine and 2 g curcumin (Shoba et al. 1998) is measured against a baseline that was undetectable or very low. The UK Committee on Toxicity noted that the control group was below the limit of detection and that only curcumin was measured (COT 2024).
  • A 2021 crossover in 30 adults that measured 15 curcuminoids and metabolites over 24 h found total curcuminoid AUC of 4,380 ± 2,330 ng·h/mL for a piperine product against 5,080 ± 2,410 for a standard 95% extract (Fança-Berthon et al. 2021).
  • In the U.S. Drug-Induced Liver Injury Network series of 10 turmeric cases, 3 of the 7 products tested also contained piperine (Halegoua-DeMarzio et al. 2023). That is a signal, not proof of cause.

Decision

Take two formulation candidates to Stage 6, chosen by the method on the curcumin solubility demonstration, each with its measured exposure relative to the standard extract as an input.

Rejected: a piperine combination, for the three reasons given.

Passes forward to Stage 6: the exposure multiple of each candidate. A higher multiple reopens the safety case.

06 · Stage 6 · Establish safety and performance evidence

A dose in milligrams is not an exposure once the formulation changes absorption

The ADI for curcumin rests on conventional curcumin fed to rats. Formulations that raised plasma exposure 8.5 and 39.1 times in one study (section 05) make a milligram-per-kilogram comparison with that ADI unreliable as a measure of exposure. The UK Committee on Toxicity has taken up this question in a discussion paper on novel formulations designed to increase oral bioavailability, with curcuminoids as a case study (COT 2025), and NCCIH states that highly bioavailable curcumin formulations may harm the liver (NCCIH).

The liver signal is documented. LiverTox describes several dozen cases of clinically apparent liver injury linked to turmeric (LiverTox). In the DILIN series, all 10 cases were enrolled since 2011. Five patients were hospitalized and 1 died, 7 carried HLA-B*35:01, and latency was 1 to 4 months (Halegoua-DeMarzio et al. 2023).

Decision

For each candidate, build the safety and exposure assessment on that formulation’s own exposure data, with study needs chosen from the known hazards and intended intake, and studies run at partner GLP laboratories where needed. The serving is set only then.

Rejected: setting the serving of an enhanced formulation from the 3 mg/kg ADI alone.

Safety gate: no known hazard at the intended exposure. If neither candidate passes, the program returns to Stage 5.

07 · Stages 7 and 8 · Scale and transfer; commercialize

At scale the earlier limits become equipment requirements and contract terms

Stage 7: what the plant must respect

At the study’s laboratory yields, 1 metric ton of milled rhizome would give about 214 kg of acetone oleoresin carrying about 77 kg of curcuminoids. Plant yields differ and must be measured; this is arithmetic on three laboratory extractions.

  • Evaporation and drying kept at low temperature (the extraction study used 40 °C) until degradation is measured, from Stage 3.
  • Acetone recovered and the residue verified on every lot against the proposed 30 mg/kg limit, from Stages 3 and 4.
  • The specification of Stage 4 met by lots made at the new scale.

Scale gate: commercial lots meet the specification and the transfer or supply terms are written.

Stage 8: what could be owned

A naturally occurring compound is not patent-eligible merely because it has been isolated (Myriad, 2013); a process, a formulation or a composition can be. The client owns its data, formulation and results. What EUTECNIQ could keep, only where the contract allows, is method know-how that is not specific to the client’s product.

Commercial outputs: a supply agreement with the Stage 4 specification as its exhibit, or a license to a formulation the company developed on its own account.

Route gate, confirmed: structure/function statements only, checked by the client’s counsel before launch.

08 · The record of what was turned down

Six alternatives rejected or deferred, each with the evidence and the stage it would have affected

Rejected or deferred alternatives in the hypothetical program
AlternativeStageReasonLater stage it would have burdened
HPLC content as proof of natural origin2Could not separate synthetic from natural curcuminoids in a published set of 27 samples4, 8: a specification that admits synthetic material
Methanol extraction3Recovery within error of acetone, poorer oleoresin, class 2 solvent4, 7: stricter residue control for no measurable gain
Ethanol extraction (deferred)3Lowest recovery and poorest oleoresin in the same study7: more material to remove on the way to a high-purity grade
Absorbance at 425 nm as the only assay4One number for all coloring matter; blind to the three curcuminoids and to synthetic origin6, 8: no composition record behind the serving
Piperine combination5Headline gain against an undetectable baseline; no higher total exposure in a 2021 crossover; present in 3 of 7 products tested in the DILIN series6: an added interaction and liver question
Serving set from the ADI alone for an enhanced formulation6The ADI rests on conventional curcumin; exposure changed by up to 39 times in one study8: a label dose without an exposure basis

Hypothetical example Sources as cited in sections 02 to 06.

09 · Limits

What this demonstration does not show

  • No EUTECNIQ data. The extraction numbers come from one laboratory, one rhizome lot and three replicates each; another lot or scale could reorder the solvents.
  • No costs. Solvent, energy and equipment costs would enter the Stage 3 decision and are not estimated here; the extraction demonstration works through energy for a different botanical.
  • No claim of benefit. Higher plasma exposure is not evidence of a health effect, and nothing here supports a disease claim.
  • No legal conclusion. New-dietary-ingredient status and label wording are questions for the client’s counsel.

Back to the Ingredient Engine · Three ways into the Engine · The investment thesis

Sources

References cited in this demonstration

  1. Barriga-Sánchez M, Sanchez-Gonzales G, Cueva-Martínez M, Medina-Cáceres EA, Villacres-Vallejo J. Comparison of conventional and supercritical CO2 extraction techniques of Curcuma longa L. oleoresin and optimization of the spray drying process. Food Sci Technol (Campinas). 2024;44:e00168. doi.org/10.5327/fst.00168 (Tables 3 and 4).
  2. Bener M, Özyürek M, Güçlü K, Apak R. Optimization of microwave-assisted extraction of curcumin from Curcuma longa L. (turmeric) and evaluation of antioxidant activity in multi-test systems. Rec Nat Prod. 2016;10(5):542–554. acgpubs.org.
  3. Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014;19(12):20091–20112. doi.org/10.3390/molecules191220091.
  4. European Medicines Agency, HMPC. Assessment report on Curcuma longa L., rhizoma. Final, 25 September 2018. ema.europa.eu.
  5. FAO JECFA. Curcumin: chemical and technical assessment, 61st meeting. FAO, 2004. fao.org.
  6. FAO JECFA. Curcumin specification, prepared at the 61st JECFA (2003), FNP 52 Add 11: assay, permitted solvents, residual solvents and lead. fao.org.
  7. WHO. JECFA database, Curcumin (INS 100i): ADI 0–3 mg/kg bw, evaluation 2003 (TRS 922). apps.who.int.
  8. EFSA ANS Panel. Scientific opinion on the re-evaluation of curcumin (E 100) as a food additive. EFSA J. 2010;8(9):1679. doi.org/10.2903/j.efsa.2010.1679.
  9. Commission Regulation (EU) No 231/2012, Annex, E 100 curcumin (consolidated text of August 18, 2026). eur-lex.europa.eu.
  10. 21 CFR 173.210 (acetone), 173.250 (methyl alcohol) and 173.270 (hexane): residues in spice oleoresins. eCFR, current to October 29, 2026. ecfr.gov.
  11. ICH Q3C(R9). Impurities: guideline for residual solvents. Step 4, January 24, 2024. pmda.go.jp.
  12. Gafner S, Orhan N, Kahraman Ç, Blumenthal M. A scoping review of turmeric adulteration based on data from six continents. Pharm Biol. 2026;64(1):87–107. doi.org/10.1080/13880209.2025.2606229.
  13. Forsyth JE, Nurunnahar S, Islam SS, et al. Turmeric means “yellow” in Bengali: lead chromate pigments added to turmeric threaten public health across Bangladesh. Environ Res. 2019;179(Pt A):108722. doi.org/10.1016/j.envres.2019.108722.
  14. Perini M, Pianezze S, Ziller L, Larcher R, Pace R. Stable isotope ratio analysis for the authentication of natural antioxidant curcuminoids from Curcuma longa (turmeric). Antioxidants. 2023;12(2):498. doi.org/10.3390/antiox12020498.
  15. Mudge EM, Brown PN. Determination of curcuminoids in turmeric raw materials and dietary supplements by HPLC: single-laboratory validation, First Action 2016.16. J AOAC Int. 2018;101(1):203–207. doi.org/10.5740/jaoacint.17-0111.
  16. PubChem Compound Summary, Curcumin (CID 969516): solubility “Insoluble in water” (HSDB). pubchem.ncbi.nlm.nih.gov.
  17. Purpura M, Lowery RP, Wilson JM, Mannan H, Münch G, Razmovski-Naumovski V. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr. 2018;57(3):929–938. doi.org/10.1007/s00394-016-1376-9.
  18. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–356. doi.org/10.1055/s-2006-957450.
  19. Fança-Berthon P, Tenon M, Le Bouter-Banon S, et al. Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a human crossover study. J Nutr. 2021;151(7):1802–1816. doi.org/10.1093/jn/nxab087.
  20. UK Committee on Toxicity. Statement on the potential risk to human health of turmeric and curcumin supplements (COT/2024/07): toxicokinetics. cot.food.gov.uk.
  21. UK Committee on Toxicity. Novel formulations of supplement compounds designed to increase oral bioavailability, Annex A, case study 2: curcuminoids (TOX/2025/09). cot.food.gov.uk.
  22. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver injury associated with turmeric: a growing problem. Ten cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. 2023;136(2):200–206. doi.org/10.1016/j.amjmed.2022.09.026.
  23. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Turmeric. NIDDK; updated June 16, 2025. PMID 31643876.
  24. National Center for Complementary and Integrative Health. Turmeric: usefulness and safety. Last updated April 2025. nccih.nih.gov.
  25. 21 U.S.C. 321(g)(1), definition of drug. law.cornell.edu.
  26. 21 CFR 101.93, Certain types of statements for dietary supplements. ecfr.gov.
  27. 21 CFR 190.6, Requirement for premarket notification. ecfr.gov.
  28. 21 CFR 111.70, Requirement to establish specifications; paragraph (b), component specifications (eCFR, current to October 20, 2026). ecfr.gov.
  29. 21 CFR 111.75, verification of specifications. ecfr.gov.
  30. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). law.cornell.edu.

Health information notice. These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease, and nothing here is medical advice.

Read the full notice

The information is for general education only. It does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed. Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to start a development project?

Tell us about an ingredient you want to specify, verify or license. Questions? Email [email protected]